

MARIE CURIE ACTIONS
(MSCF-CT-2006-046108)

Translational Research in Paediatric Rheumatology (TRiPR)

FOURTH CONFERENCE

Biological Agents and Emerging Treatments in the Management of Rheumatic Diseases

May 27th – 30th, 2010

Villa Quartara
Genoa, Italy

Conference Chair

Alberto Martini (Genoa)

Scientific Committee

Abul K Abbas (San Francisco)

Salvatore Albani (San Diego)

Ornella Della Casa Alberighi (Genoa)

Wietse Kuis (Utrecht)

Tore K. Kvien (Oslo)

Pierre Miossec (Lyon)

Angelo Ravelli (Genoa)

Nicola Ruperto (Genoa)

Costantino Pitzalis (London)

Provisional Programme



Giannina Gaslini
Institute



International School
of Pediatric Science



University of
Genoa



PRINTO
Pediatric
Rheumatology
International Trials
Organisation



PRÉS
Paediatric Rheumatology
European Society



www.triapr.sispge.com

The Project

“Translational **R**esearch in **P**aediatric **R**heumatology” - **TRiPR** - is a series of four events financed by the European Union’s Marie Curie Actions programme for the training and mobility of researchers (Project no. MSCF-CT-2006-046108). TRiPR has the overriding goal of acquainting younger generations of European researchers and clinicians with the key issues underpinning the development of new therapeutic strategies for paediatric rheumatic diseases, seeking above all to enhance their translational research skills in the field.

The Event

Over the last decade biological therapies have represented a major advancement in the treatment of rheumatic diseases. Despite this progress, however, several problems remain. At the same time, breakthroughs in basic and applied research are yielding a myriad of new potential targets for therapies.

The final conference in the TRiPR series of events - *Biological Agents and Emerging Treatments in the Management of Rheumatic Diseases* - will address the treatment of both adult and childhood rheumatic diseases with the purpose of reviewing and discussing the progress that has been achieved thus far, the unmet needs that are still faced, and the potential new treatments that the future holds in store. A final session will be devoted to strategies to improve methodologies of translational research on and clinical development in common, as well as rare, forms of rheumatic disorders.

Thursday, May 27th

Session I **Assessing drug response in chronic arthritis**

- How to define clinical response in RA
Theodore Pincus, New York
- How to define clinical response in JIA
Angelo Ravelli, Genoa
- The value of MRI in RA
Marco Cimmino, Genoa
- The value of MRI in JIA
Clara Malattia, Genoa
- The value of ultrasonography in RA
Walter Grassi, Jesi
- The value of ultrasonography in JIA
Carlo Martinoli, Genoa

Session II **Biological agents**

in Rheumatoid Arthritis

- Anti-TNF registries in adults: lessons learned
Ronald Van Vollenhoven, Stockholm
- Tocilizumab, Abatacept and Rituximab: the added value
Stefano Bombardieri, Pisa
- The unmet needs in RA
Tore K. Kvien, Oslo

in Juvenile Idiopathic Arthritis

- Etanercept: lessons learned
Daniel Lovell, Cincinnati
- Other biological agents
Nicola Ruperto, Genoa
- The case of systemic JIA
Alberto Martini, Genoa

Friday, May 28th

Session III **Present and future therapies**

- Optimizing glucocorticoid therapy in rheumatic diseases
Maurizio Cutolo, Genoa
- Spondyloarthropathies
Dirk Elewaut, Ghent
- Systemic lupus erythematosus
Dimitrios Boumpas, Heraklion
- Dermatomyositis
Lucy Wedderburn, London
- Vasculitis
Loic Guillevin, Paris
- Scleroderma
Oliver Distler, Zurich
- Autoinflammatory diseases
Marco Gattorno, Genoa

Saturday, May 29th

Session IV Potential new targets for treatment

- Kinase inhibitors
Kamran Ghoreschi, Bethesda
- Genetic manipulation of the inflammatory response
Christian Jorgensen, Montpellier
- Blocking IL-17
Pierre Miossec, Lyon
- Anti-interferon- γ
Virginia Pascual, Dallas
- Antigen specific therapy
Berent Prakken, Utrecht
- P2XR antagonists
Elisabetta Traggiai, Genoa
- Neuroinflammation: the cholinergic anti-inflammatory pathway
Paul-Peter Tak, Amsterdam
- Targets in the bone
Georg Schett, Erlangen
- Novel new small molecule and biologic targets for chronic inflammatory disease
Harsukh Parmar, Loughborough
- Beyond IL-1: new molecular targets in autoinflammatory diseases
Daniel Kastner, Bethesda
- Targeting Toll-like receptors
Luke O'Neill, Dublin
- Dendritic cells
John D. Isaacs, Newcastle
- B cells
Andreas Radbruch, Berlin
- Regulatory T cells and IL-2
Abul K. Abbas, San Francisco

Sunday, May 30th

Session V Facilitating translational research and clinical development in small populations

- Can synovial pathobiology inform treatment in RA?
Costantino Pitzalis, London
- Biomarkers in rheumatic diseases
Dirk Föll, Münster
- Clinical trials in small populations: issues and challenges
Edward Giannini, Cincinnati
- The role of pharmacokinetics for clinical development in small populations
Ornella Della Casa Alberighi, Genoa
- Pharmacovigilance in small populations
Taner Vardar, Geneva
- Translational medicine: from regional challenges to global solutions
Salvatore Albani, San Diego